# Thalidomide in Treating Patients With Myelodysplastic Syndrome

> **NCT00015990** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndromes
- Previously Treated Myelodysplastic Syndromes
- Refractory Anemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Excess Blasts in Transformation
- Refractory Anemia With Ringed Sideroblasts
- Secondary Myelodysplastic Syndromes

## Interventions

- **DRUG:** thalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00015990
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00015990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00015990, "Thalidomide in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00015990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*